Somatropin [rDNA origin] Articles

Japanese Pharma market seeing more foreign entrants

21 January 2010

Sandoz gets FDA approval for Omnitrope

8 September 2008

EMEA creates precedent for biosimilars with approvals for biogeneric versions of Epogen

2 July 2007

Pharmacia pleads guilty to kickback charges

7 May 2007

Pfizer units settle with DOJ for $34.7M

9 April 2007

Biogenerics could "save $14B in Rx costs for Medicare Part B," claims report

15 January 2007

Direct molecular evolution: lifecycle management for biologics

14 August 2006

Omnitrope's US appro sets no precedents for biogenerics, says Wood Mackenzie

19 June 2006

Sandoz/Novartis' Omnitrope is first "generic biological" to be approved by US FDA

12 June 2006

Sandoz plans five more "biosimilars" launches

22 May 2006

"Western biotechs not threatened by generic east," new study finds

8 May 2006

EC approves Sandoz' Omnitrope

24 April 2006

CHMP gives nod to Sandoz' Omnitrope

6 February 2006

EMEA opens the doors for "biosimilars" with Omnitrope

6 February 2006

Novartis suit seeks FDA ruling on follow-on HGH

19 September 2005

NICE guidance implementation in England/ Wales studied, shows mixed results

31 May 2004

New use for Pfizer's Genotropin in EU

14 July 2003

Pharmacia gets US approval for acromegaly treatment Somavert

7 April 2003

Drugs giant Pfizer makes $60 billion all-share offer for Pharmacia

22 July 2002

Swedish pharma continues steady growth; 26.7bn kronor sales in 2001

8 July 2002

Somatropin OK for GH deficiency: UK NICE

3 June 2002

Pharmacia sales take a dip in first quarter

29 April 2002

Pharmacia 4th-qtr profits take a dip but Celebrex still selling well

11 February 2002

Pharmacia EPS rises 24% in third quarter

24 October 2001

Pharmacia earnings up 20%, sales rise 5%

25 July 2001

Pharmacia sees 19% EPS rise and Rx pharma sales increase 15% in 1st qtr

26 April 2001

Pharmacia acquires remainder of Sensus

8 March 2001

Pharmacia fourth-quarter earnings jump 32%, driven by Celebrex sales

13 February 2001

Novo and Pharmacia settle hGH dispute

14 November 2000

Strong sales of Celebrex lead to 57% leap in earnings per share at Pharmacia

1 November 2000

Pharmacia Corp sales increase 16% boosted by Celebrex and Xalatan

26 July 2000

Pharmacia's EPS up 27% in 1st quarter

26 April 2000

Pharmacia & Upjohn and Monsanto both post strong results for 1999

11 February 2000

P&U continues turnaround, looking for 1999 double-digit growth

29 October 1999

Pharmacia & Upjohn net income up 47%

2 August 1999

Gen-eng drug market growth "to be driven by products not yet launched"

20 July 1999

Pharmacia & Upjohn earnings up 17%

5 May 1999

P&U posts strong growth for 1998

12 February 1999

Pharmacia & Upjohn Posts Strong Growth For 3rd Qtr

3 November 1998

Pharmacia & Upjohn Turnaround Continuing

31 July 1998

Stock Commentary Tokyo

16 July 1998

Strong 1st Qtr Growth In Swedish Pharma Market

15 May 1998

P&U Sales Up, Says Turnaround Is On Track

30 April 1998

P&U 1997 Sales Slide, Earnings Hit By Charges

18 February 1998

P&U Calls Halt To Off-Label Use Of Genotropin

4 December 1997

News In Brief

7 November 1997

P&U Profits Slump On Currency And Generic Competition

31 July 1997

Biogen And P&U Settle Litigation

7 October 1996

Net Income Falls At Pharmacia & Upjohn

12 August 1996

Sweden's Pharma Market Expanded 12.7% In 1995

4 March 1996

Pharmacia & Upjohn First Combined Results

26 February 1996

Pharmacia Sees Downturn In Last Independent Results

20 November 1995

Net Profit Growth At Pharmacia

4 September 1995

Pharmacia Results Down But Ahead Of Expectations

22 May 1995

Productivity Improvements Boost Pharmacia Earnings

20 March 1995

Pharmacia Pipeline Promises Future Growth

20 March 1995

CPMP OKs Pharmacia's Igef And Genotropin

9 January 1995

Pharmacia's Sales Decline But Profits Rise

21 November 1994

2.8 Bill Kroner Interim Profits For Pharmacia

5 September 1994

PHARMACIA OPERATING INCOME ROCKETS

23 May 1994

GENENTECH'S hGH APPROVED IN USA

21 March 1994

NET PROFITS LEAP AT SUMITOMO PHARMA

7 March 1994

SWEDISH PHARMA MARKET GROWTH SLOWDOWN

28 February 1994

RAPID GROWTH FOR WORLD ENDOCRINEs

25 October 1993

ANALYSTS SAY PROCORDIA SPLIT IS SOUND LOGIC

19 July 1993

OPERATING PROFIT FALLS AT PROCORDIA

17 May 1993

SWEDEN'S PHARMA MARKET IN 1992

5 April 1993

WORLD ENDOCRINE MARKET AND FORECASTS

29 March 1993

PROCORDIA/KABI PHARMACIA PROFITS UP

22 March 1993

PHARMACEUTICAL DESIGN: EPITOPE SELECTION

15 March 1993

NET PROFIT FALLS AT SUMITOMO

1 March 1993

KABI PHARMACIA IS PROCORDIA CROWN JEWEL

18 January 1993

SWEDEN'S PHARMA MARKET IN 1991

11 May 1992

Showing 1-73 of 73 articles

Go to beginningPrevious
  • 1
NextGo to end